RATIONALE: Benzodiazepines (BZs) are effective anxiolytics and hypnotics, but their use is limited by unwanted side effects, such as motor impairment. OBJECTIVES: To assess the contribution of alpha1 subunit-containing gamma-aminobutyric acid(A) (GABA(A)) receptor subtypes to the motor-impairing effects of BZs, the present study evaluated two observable measures of motor coordination (balance on a pole, resistance to hind-limb flexion) engendered by nonselective and selective BZ-site agonists in squirrel monkeys. MATERIALS AND METHODS: Multiple doses of nonselective BZs (triazolam, alprazolam, diazepam, and chlordiazepoxide) and alpha1 subunit-preferring agonists (zolpidem and zaleplon) were administered to adult male squirrel monkeys (N = 4-6), and experimenters rated the monkey's ability to balance on a horizontal pole ("ataxic-like effects"), as well as the degree of resistance to hind-limb flexion ("myorelaxant-like effects"). RESULTS: Administration of all BZ-type drugs resulted in ataxic-like and myorelaxant-like effects. Pretreatment with the alpha1 subunit-preferring antagonist beta-carboline-3-carboxylate-t-butyl ester (betaCCT) attenuated the ataxic-like effects engendered by both types of drugs. However, betaCCT was largely ineffective at blocking the ability of both BZs and non-BZs to induce myorelaxant-like effects. CONCLUSIONS: These experiments demonstrate dose-dependent motor impairment in squirrel monkeys using quantitative behavioral observation techniques. Altogether, these findings suggest a lack of a prominent role for alpha1 subunit-containing receptors in the alteration of hind-limb flexion, a putative measure of myorelaxation, induced by BZ-type drugs in monkeys.
RATIONALE: Benzodiazepines (BZs) are effective anxiolytics and hypnotics, but their use is limited by unwanted side effects, such as motor impairment. OBJECTIVES: To assess the contribution of alpha1 subunit-containing gamma-aminobutyric acid(A) (GABA(A)) receptor subtypes to the motor-impairing effects of BZs, the present study evaluated two observable measures of motor coordination (balance on a pole, resistance to hind-limb flexion) engendered by nonselective and selective BZ-site agonists in squirrel monkeys. MATERIALS AND METHODS: Multiple doses of nonselective BZs (triazolam, alprazolam, diazepam, and chlordiazepoxide) and alpha1 subunit-preferring agonists (zolpidem and zaleplon) were administered to adult male squirrel monkeys (N = 4-6), and experimenters rated the monkey's ability to balance on a horizontal pole ("ataxic-like effects"), as well as the degree of resistance to hind-limb flexion ("myorelaxant-like effects"). RESULTS: Administration of all BZ-type drugs resulted in ataxic-like and myorelaxant-like effects. Pretreatment with the alpha1 subunit-preferring antagonist beta-carboline-3-carboxylate-t-butyl ester (betaCCT) attenuated the ataxic-like effects engendered by both types of drugs. However, betaCCT was largely ineffective at blocking the ability of both BZs and non-BZs to induce myorelaxant-like effects. CONCLUSIONS: These experiments demonstrate dose-dependent motor impairment in squirrel monkeys using quantitative behavioral observation techniques. Altogether, these findings suggest a lack of a prominent role for alpha1 subunit-containing receptors in the alteration of hind-limb flexion, a putative measure of myorelaxation, induced by BZ-type drugs in monkeys.
Authors: Neil Collinson; Frederick M Kuenzi; Wolfgang Jarolimek; Karen A Maubach; Rosa Cothliff; Cyrille Sur; Alison Smith; Franklin M Otu; Owain Howell; John R Atack; Ruth M McKernan; Guy R Seabrook; Gerry R Dawson; Paul J Whiting; Thomas W Rosahl Journal: J Neurosci Date: 2002-07-01 Impact factor: 6.167
Authors: G Griebel; G Perrault; V Letang; P Granger; P Avenet; H Schoemaker; D J Sanger Journal: Psychopharmacology (Berl) Date: 1999-09 Impact factor: 4.530
Authors: Sarah A Nickolls; Rachel Gurrell; Guido van Amerongen; Juha Kammonen; Lishuang Cao; Adam R Brown; Clara Stead; Andy Mead; Christine Watson; Cathleen Hsu; Robert M Owen; Andy Pike; Rebecca L Fish; Laigao Chen; Ruolun Qiu; Evan D Morris; Gang Feng; Mark Whitlock; Donal Gorman; Joop van Gerven; David S Reynolds; Pinky Dua; Richard P Butt Journal: Br J Pharmacol Date: 2018-01-18 Impact factor: 8.739
Authors: Stephanie C Licata; Steven B Lowen; George H Trksak; Robert R Maclean; Scott E Lukas Journal: Prog Neuropsychopharmacol Biol Psychiatry Date: 2011-05-30 Impact factor: 5.067
Authors: Bradford D Fischer; John R Atack; Donna M Platt; David S Reynolds; Gerard R Dawson; James K Rowlett Journal: Psychopharmacology (Berl) Date: 2010-12-30 Impact factor: 4.530
Authors: August F Holtyn; V V N Phani Babu Tiruveedhula; Michael Rajesh Stephen; James M Cook; Elise M Weerts Journal: Drug Alcohol Depend Date: 2016-11-04 Impact factor: 4.492
Authors: Marija Milić; Jovana Divljaković; Sundari Rallapalli; Michael L van Linn; Tamara Timić; James M Cook; Miroslav M Savić Journal: Behav Pharmacol Date: 2012-04 Impact factor: 2.293
Authors: Srđan Joksimović; Zdravko Varagic; Jovana Kovačević; Michael Van Linn; Marija Milić; Sundari Rallapalli; Tamara Timić; Werner Sieghart; James M Cook; Miroslav M Savić Journal: Psychopharmacology (Berl) Date: 2013-05-18 Impact factor: 4.530
Authors: Stephanie C Licata; J Eric Jensen; David M Penetar; Andrew P Prescot; Scott E Lukas; Perry F Renshaw Journal: Psychopharmacology (Berl) Date: 2009-01-06 Impact factor: 4.530
Authors: Michael M Poe; Kashi Reddy Methuku; Guanguan Li; Ashwini R Verma; Kelly A Teske; Douglas C Stafford; Leggy A Arnold; Jeffrey W Cramer; Timothy M Jones; Rok Cerne; Michael J Krambis; Jeffrey M Witkin; Enrique Jambrina; Sabah Rehman; Margot Ernst; James M Cook; Jeffrey M Schkeryantz Journal: J Med Chem Date: 2016-11-28 Impact factor: 7.446